MRK - Pharma Giants Shift Stance Embrace Medicare Negotiations Amid Rising Drug Costs | Benzinga
AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiations despite having previously sued to halt the process.
Among the first ten drugs selected for price negotiations with Medicare are AstraZeneca's Type 2 diabetes drug, Farxiga, Boehringer Ingelheim's diabetes medication, Jardiance, and Bristol Myers Squibb's blood thinner, Eliquis.
Related: Legal Twist In Drug Price Negotiation: Federal Judge Quits Case Amid Allegations Of ...